

FACT SHEET

MANULIFE DANA EKUITAS ASIA PASIFIK - IDR

OCT 2021

Investment Objective

To achieve long term capital growth by investing mainly in offshore instruments consist of 80% - 100% in equity securities which are sold through public offerings and / or traded at the stock exchanges in the Asia Pacific region.

Fund Information

 Inception Date
 :
 5 Dec 16

 Fund Size
 :
 Rp 965.41 bn

 Fund Currency
 :
 IDR

 Type of fund
 :
 Equity

 Valuation
 :
 Daily

Custodian Bank : Bank DBS Indonesia

Annual Management Fee : 2.50%


Net Asset Value/Unit ³⁾ : IDR 18,341.00

Bloomberg Code : MAAPCID IJ


Performance Since Inception



Monthly Performance Last 3 Years



Risk Classification



Top 5 Holdings

- 1 Samsung Electronics Co Ltd Common Stock
- 2 CSL Ltd
- 3 CSL Ltd
- 4 Reliance Industries Ltd
- 5 LG Chem Ltd

Fund Performance

Performance in IDR per (29/10/21)								
	1 mo	3 mo	6 mo	YTD	1 yr	3 yr ¹⁾	5 yr ¹⁾	Since Inception 1)
MDEAP (IDR)	1.07%	-2.40%	-5.65%	1.16%	9.43%	5.45%	n/a	6.43%
BM ²⁾	-0.77%	-4.80%	-6.35%	1.38%	16.98%	10.42%	n/a	11.99%
			Yearly Pe	erformance)			
	2020	2019	2018	2017	2016	2015	2014	2013
MDEAP (IDR)	10.28%	12.84%	-9.95%	23.08%	n/a	n/a	n/a	n/a
BM ²⁾	25.88%	11.16%	-9.78%	37.77%	n/a	n/a	n/a	n/a

Note

- Annualized (1 year = 365 days) and using compound method (for products that have been more than one year old since inception).
- 2) The benchmark is FTSE Sharia Asia Pacific ex Japan in IDR terms.
- The Net Asset Value / Unit has calculated the costs, including fees related to transaction and transaction settlement
 as well as administration and recording

Investment Manager Commentary

Asia equity market was volatile in October amid concern of global supply chain disruption and rising COVID-19 case in China. China's approach of 'zero COVID' policy forces strict lockdown that risks economic growth. China manufacturing PMI fell to 49.2 in October from 49.6 the previous month, indicating contraction in manufacturing activity. China GDP growth fell to 4.9% YoY in Q3-2021 from 7.9% the previous quarter, amid policy reforms in various sectors and pressure in the property sector. Apart from that, uncertainty from the global market also overshadowed the market with US debt ceiling negotiation in US Congress and The Fed's monetary policy. Portfolio allocation in healthcare and materials contributed positive attribution, meanwhile allocation in financials and consumer staples contributed negative attribution to performance.

Disclaimer: This report is prepared by PT Asuransi Jiwa Manulife Indonesia only for information purposes and not to be used as a sales offering or proposal. Although this report has been prepared meticulously, PT Asuransi Jiwa Manulife Indonesia does not guarantee its accuracy, sufficiency or completeness, and is not responsible for any consequences and actions which are based on the information stated herein. Investments in capital market instruments are subject to various risks which include, but not limited to, market risk, credit risk, interest rate risk, exchange rate risk (particularly in Fund which has allocation in offshore investment instruments in different currencies than the Fund's currency), liquidity risk and other risks which could result in performance volability. Therefore, the performance of this Fund is not guaranteed, the unit price of each Fund may go up or down and past performance does not necessarily indicative of future performance.

Manulife Indonesia

Established in 2015, PT Asuransi Jiwa Manulife Indonesia (Manulife Indonesia) is part of Manulife Financial Corporation Group, a Canadian financial services group that operates in Asia, Canada and the United States
Manulife Indonesia offers a wide range of financial services, including life insurance, accident and health insurance, investment and pension plans to individual customers and group clients in Indonesia. Through a network
of almost 11.000 employees and professional agents spread across more than 25 sales offices. Manulife Indonesia serves more than 2 million customers in Indonesia.

PT Asuransi Jiwa Manulife Indonesia is registered and supervised by the Otoritas Jasa Keuangan (OJK). To learn more about Manulife Indonesia, follow us on Facebook, Twitter, Instagram, YouTube, or visit









